Sector: Health Care
Director information for FORTREA HOLDINGS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Amrit Ray | ["General Management and Business Operations","Technology","Finance/Accounting","Mergers and Acquisitions","Risk Management","International Business","Healthcare/Drug Development","Quality and Regulatory","Science and Medicine","Spin Experience"] | [] | 2026 | ||
| Anshul Thakral | Chief Executive Officer and Director | 48 | ["General Management and Business Operations","CEO Experience","Finance/Accounting","Mergers and Acquisitions","Risk Management","International Business","Healthcare/Drug Development","Spin Experience","More than 25 years of experience in the CRO, pharmaceutical, and biotech industries","General manager","Management consultant","Commercial leader","Entrepreneur","Co-Founder and Chief Executive Officer of Launch Therapeutics","Former Global Head of PPD Biotech at PPD, Inc.","Chief Commercial Officer and Executive Vice President at PPD","Ran the global life sciences business unit at Gerson Lehrman Group","Consultant at McKinsey & Company","Bachelor of Science and Master of Science in Biomedical Engineering from Johns Hopkins University","Master of Business Administration from the Wharton School at the University of Pennsylvania"] | [] | 2026 |
| David Smith | Director | 60 | ["General Management and Business Operations","Finance/Accounting","Mergers and Acquisitions","Risk Management","International Business","Healthcare/Drug Development","Science and Medicine","Spin Experience","Over 25 years of pharmaceutical industry experience","Former Executive Vice President and Chief Financial Officer for Charles River Laboratories International, Inc.","Served as Chief Executive Officer for Galapagos Services Division","Corporate Senior Vice President at Charles River","Promoted to Chief Financial Officer in August 2015","Led Charles River into the S&P 500 in May 2021","Former Chief Financial Officer at Cambridge University Hospitals","Former Chief Financial Officer at Galapagos NV","Held management positions at AstraZeneca in multiple countries","Trained as a Chartered Accountant","Bachelor of Sciences Honors degree in Molecular Biophysics from the University of Leeds"] | [] | 2026 |
| Dr. Amrit Ray | Director | 53 | ["physician researcher and advisor to life science companies","over 25 years of biomedical research and pharmaceutical industry experience","Chief Patient Officer at Biohaven Pharmaceuticals","Global President, Head of R&D and Medical at Pfizer","Chief Medical Officer and Chief Safety Officer for global pharmaceuticals at Johnson & Johnson","degrees in Immunology and Medicine from Edinburgh University","Master of Business Administration from the Tuck School of Business at Dartmouth College","Visiting Professor of Practice at the Faculty of Medical Sciences of Newcastle University, UK","Board of Trustees at The Hastings Center for Bioethics","director of Ultragenyx Pharmaceutical Inc."] | [] | 2026 |
| Edward Pesicka | Director | 59 | ["General Management and Business Operations","CFO Experience","Technology","Finance/Accounting","Mergers and Acquisitions","Risk Management","International Business","Healthcare/Drug Development","Science and Medicine","Spin Experience","President and Chief Executive Officer at Owens & Minor, Inc.","Independent consultant and advisor in healthcare, life science and distribution industries","Chief Commercial Officer and Senior Vice President at Thermo Fisher Scientific Inc.","Experience in finance department at TRW Inc.","Auditor at PricewaterhouseCoopers","MBA from Weatherhead School of Management at Case Western Reserve University","BA in Business Administration and Management from Muskingum College"] | [] | 2026 |
| Erin L. Russell | Director | 52 | ["Board member of Modivcare since February 2025","Board member of eHealth, Inc. since July 2021","Board member of Kadant Inc. since January 2019","Previous board experience with Tivity Health Inc., DeVilbiss Healthcare LLC, DynaVox Inc., and 21st Century Oncology Inc.","Industry advisor at Starboard Value Acquisition Corporation from August 2020 until August 2021","16 years as a principal of Vestar Capital Partners, L.P.","Chair of the board of St. Thomas Aquinas Catholic School since June 2018","Chair of the advisory board of McIntire School of Commerce since June 2016","Member of the advisory board of the Jefferson Scholars Foundation since April 2008","Bachelor of Science in Commerce from the University of Virginia","Master of Business Administration from Harvard Business School","General Management and Business Operations","CFO Experience","Human Resources","Healthcare/Drug Development","Quality and Regulatory","Science and Medicine","Spin Experience"] | [] | 2026 |
| Machelle Sanders | Director | 62 | ["General Management and Business Operations","Technology","Finance/Accounting","Mergers and Acquisitions","International Business","Healthcare/Drug Development","Science and Medicine","Spin Experience","Accomplished biopharmaceutical leader","Expertise in quality, compliance, operations, and organizational transformation","Senior leadership roles at Biogen, Inc.","Served as North Carolina’s Secretary of Commerce","Served as Secretary of Administration","Board member at BioCryst Pharmaceuticals, Inc.","Previous board member of Novan, Inc. and Radius Health, Inc.","Bachelor of Science in Biochemistry","Master’s in Health Administration","Continued executive development through Stanford University’s Directors’ Consortium"] | ["science committee","chairperson of the compensation committee"] | 2026 |
| Peter M. Neupert | Director; Chairman and Former Interim Chief Executive Officer | 70 | ["Served as Operating Partner at Health Evolution Partners","Former Corporate Vice President, Health Solutions Group at Microsoft","Former Chief Executive Officer and Chairman of drugstore.com","Former Corporate Vice President for News and Publishing at Microsoft","Director of Labcorp","Director of Adaptive Biotechnologies Corporation","Former member of the board of directors of NextGen Healthcare, Inc.","Former member of the Board of Trustees of Fred Hutchinson Cancer Research Center","Bachelor of Arts in Philosophy from Colorado College","Master of Business Administration from the Tuck School of Business at Dartmouth College","General Management and Business Operations","CEO Experience","Technology","Finance/Accounting","Mergers and Acquisitions","Risk Management","International Business","Healthcare/Drug Development","Science and Medicine","Spin Experience"] | [] | 2026 |
| Thomas Pike | Former Chairman and Chief Executive Officer | [] | [] | 2026 | |
| William J. Sharbaugh | Director | 63 | ["Extensive experience in the biopharmaceutical and life sciences industry","Served in executive and board roles for more than three decades","Chairman of the board of Ora Clinical","Member of the board of directors of Launch Therapeutics, Inc.","Previously served on the board of directors of BioCareSD, Inc. and Alcami Corporation","Chief operating officer for PPD from 2007 to 2021","B.S from the U.S. Military Academy at West Point","M.S. in the Management of Technology from the Wharton School and the School of Engineering at the University of Pennsylvania","M.S in Regulatory Affairs and Quality Assurance from Temple University School of Pharmacy","M.A. in International Relations from Boston University School of Arts and Sciences","General Management and Business Operations","Finance/Accounting","Mergers and Acquisitions","Risk Management","International Business","Healthcare/Drug Development","Quality and Regulatory","Science and Medicine","Spin Experience"] | [] | 2026 |
